Dupilumab, a fully human Ig4 monoclonal antibody directed against the Interleukin-4 Receptor subunit alpha (IL-4Rα) of IL-4 and IL-13 receptors, is a biologic therapy that has revolutionized the treatment of AD, with landmark trials demonstrating its efficacy in significantly reducing pruritus.12, 13 Janus Kinase (JAK) inhibitors have also been increasingly used in patients with AD. This evidence concerns the gene IL4 and Pruritus.